Evotec price target lowered to $11 from $14 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Evotec to $11 from $14 and keeps a Buy rating on the shares following the Q4 report. The company has “opportunities abound” but near-term uncertainty impacts investor sentiment, the analyst tells investors in a research note. The firm continues to like Evotec’s platform and sees it positioned to benefit from the evolving landscape for research and development, but drops the target to reflect some near-term uncertainty in the business.